参考文献/References:
[1]Zhang Y, Fu F, Hu H, et al. Gefitinib as neoadjuvant therapy for resectable stage Ⅱ-ⅢA nonsmall cell lung cancer: A phase Ⅱ study. J Thorac Cardiovasc Surg,2021,161(2):434-442.
[2]Xiong L, Lou Y, Bai H, et al. Efficacy of erlotinib as neoadjuvant regimen in EGFRmutant locally advanced nonsmall cell lung cancer patients. J Int Med Res,2020,48(4):300060519887275.
[3]Zhong W, Chen K, Chen C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFRmutant nonsmallcell lung cancer (EMERGINGCTONG 1103): A randomized phase Ⅱstudy. J Clin Oncol,2019,37(25):2235-2245.
[4]李学昌，齐文杰，刘军强，等.吉非替尼术前新辅助治疗肺腺癌1例.临床肿瘤学杂志,2014,19(10):959-960.
[5]韩斌，李川，葛楠，等.ⅢA期非小细胞肺癌术前靶向治疗对手术效果影响.齐鲁医学杂志,2017,32(3):274-275.
[6]Cui JW, Zhou Q, Lu S, et al. The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multipleparameter framework to assess the value of lung cancer treatment options. Transl Lung Cancer Res,2021,10(8):3594-3607.
[7]Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutationpositive nonsmallcell lung cancer(EVAN): a randomised, openlabel, phase 2 trial. Lancet Respir Med,2018,6(11):863-873.
[8]Zhong W, Wang Q, Mao W, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA(N1-N2) EGFRmutant NSCLC(ADJUVANT/CTONG1104): a randomised, openlabel, phase 3 study. Lancet Oncol,2018,19(1):139-148.
[9]Kelly K, Altorki N, Eberhardt W, et al. Adjuvant Erlotinib versus placebo in patients with stage ⅠB-ⅢA nonsmallcell lung cancer (RADIANT): a randomized, doubleblind, phase Ⅲ trial. J Clin Oncol,2015,33(34):4007-4014.
[10]Goss G, O’callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected nonsmallcell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol,2013,31(27):3320-3326.